Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19
(World News Austria)

July 13, 2020 Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19 Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects Successfully Completed Pre-Clinical Research On AVA-011, Including Tumor Cytotoxicity Studies; Expect to Launch First-In-Human Trial in Q1 2021 Filed Three Provisional Patents on Unique QTY Code Protein Design Platform that Combats the Cytokine Storm Associated With COVID-19 Lung Damage and Mortality Advances Novel Intranasal and Oral COVID-19...